Eagle pharmaceuticals, inc. (EGRX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13
Cash flows from operating activities:
Net Income (Loss) Attributable to Parent

2,469

14,313

25,898

42,326

38,260

31,903

28,398

29,791

31,635

51,943

100,159

96,678

105,273

81,453

25,371

3,253

-18,022

2,571

-4,154

-3,089

2,153

-20,228

-17,977

0

0

0

Adjustments to reconcile net income to net cash provided by operating activities:
Deferred income taxes

349

152

-4,683

-4,132

-2,632

-2,468

7,188

10,458

12,954

17,289

-17,975

-21,748

-25,904

-30,116

0

0

0

-

-

-

-

0

-

-

-

-

Depreciation expense

2,100

2,131

1,716

1,477

1,317

1,155

1,193

1,183

1,077

932

837

777

697

641

542

386

240

112

44

57

69

86

104

0

0

0

Amortization expense

2,556

2,520

2,489

2,459

2,475

2,515

2,596

2,708

2,773

2,815

2,622

2,111

1,556

948

461

260

104

0

0

0

0

0

-

-

-

-

Fair value adjustments on equity investment

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

23,688

21,998

21,385

20,206

19,559

19,082

18,323

17,579

16,541

15,429

13,847

12,369

11,092

9,768

8,648

7,747

6,536

4,051

3,226

2,101

1,056

812

606

0

0

0

Change in fair value of contingent consideration

-

-

-

-

-

-763

-2,536

-8,988

-7,776

-7,377

-5,274

1,410

1,224

957

627

395

159

0

0

0

0

0

-

-

-

-

Amortization of debt issuance costs

451

480

376

376

376

376

376

344

316

222

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

-

-

Gain (Loss) on Disposition of Assets

-

-

-

-

-

-

-

-

-

-

-

-

-

1,750

1,750

1,750

1,750

0

0

0

0

0

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

383

574

0

0

0

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-273

-273

-273

-273

0

0

0

0

-

Changes in operating assets and liabilities which provided (used) cash:
Accounts receivable

-9,438

-18,481

-33,649

-9,064

10,504

12,665

6,860

16,173

-31,316

11,627

24,543

1,195

58,208

15,919

34,832

39,045

16,018

14,311

4,922

6,270

2,688

5,364

2,172

0

0

0

Inventories

-1,832

-1,739

-26

5,419

6,494

5,556

4,765

4,958

3,126

2,379

-2,228

-2,776

-4,746

-12,303

-242

4,038

5,743

13,800

6,054

1,996

2,018

1,242

1,294

0

0

0

Prepaid expenses and other current assets

4,736

4,841

-10,294

-20,208

-7,688

-4,838

6,943

8,405

-259

-1,993

2,490

10,056

5,995

9,430

919

85

806

323

3,046

636

507

1,271

-192

0

0

0

Other assets

-

-

-

-

-

-

-

-

-

0

37

75

76

0

0

0

49

-

66

60

1

0

0

0

0

-

Accounts payable

-7,030

-4,455

3,688

-970

7,433

-2,064

-7,083

393

-15,399

-8,460

-2,893

526

8,541

10,668

-2,544

6,648

4,910

356

10,089

2,263

2,927

1,155

2,867

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,000

-6,000

-6,260

-6,585

-520

-585

0

-3,110

-3,500

-3,435

0

0

0

Accrued expenses and other liabilities

-3,088

4,067

4,260

5,177

9,334

8,128

2,429

5,292

-1,547

-9,096

-1,291

-5,804

-5,310

-316

6,892

9,431

4,480

11,873

4,401

6,070

8,012

7,428

6,692

0

0

0

Other assets and other long-term liabilities, net

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by operating activities

32,963

55,986

97,295

90,369

73,644

52,384

40,197

44,395

76,276

58,919

72,553

77,835

37,663

53,207

-3,147

-22,950

-32,446

-9,718

-794

-1,287

6,166

-21,741

-13,843

0

0

0

Cash flows from investing activities:
Purchase of equity investment security

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

1,072

777

728

457

291

133

2,782

3,571

3,779

4,436

2,213

1,570

1,462

1,590

1,566

2,458

2,642

1,881

1,409

345

65

50

46

0

0

0

Purchase of short term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

62,000

62,000

78,000

152,001

105,999

105,999

109,998

35,997

19,999

0

0

0

-

Maturities of short term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

62,000

86,000

167,999

167,999

105,999

101,998

19,999

19,999

19,999

0

0

0

0

Payments to Acquire Businesses, Gross

-

-

-

-

-

-

-

-

-

-

-

-

-

4,850

4,850

4,850

4,850

0

0

0

0

0

-

-

-

-

Payment for Ryanodex intangible asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Purchase of Eagle Biologics, net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from sale of diclofenac-misoprostol

-

-

-

-

-

-

-

-

-

-

-

-

-

1,750

1,750

1,750

1,750

0

0

0

0

0

-

-

-

-

Net cash used in investing activities

-18,572

-777

-728

-457

-291

-133

-2,782

-4,321

-4,529

-5,186

-30,073

-42,680

-42,572

-45,800

5,334

84,441

10,256

-1,881

-5,410

-90,344

-16,063

-50

-20,045

0

0

0

Cash flows from financing activities:
Payments for employee net option exercises

-

-

-

-

-

4,877

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred IPO costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-499

0

0

0

Series C preferred stock offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from exercise of preferred stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

21

0

0

0

-

Proceeds from issuance of common stock from initial public offering, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from issuance of common stock from follow-on public offering, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

54,331

54,331

0

0

0

-

-

-

-

Proceeds from common stock option exercises

548

260

92

2,002

7,491

8,615

8,774

6,876

3,367

4,338

6,298

7,749

5,756

3,619

1,872

386

918

1,482

1,130

1,195

663

99

65

0

0

0

Payment of debt financing costs

-

-

-

-

-

-

-

-

-

1,192

1,192

482

482

0

0

0

0

-

-

-

-

-

-

-

-

-

Employee withholding taxes related to stock-based awards

1,276

198

198

198

198

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of contingent consideration

-

-

-

-

-

15,000

15,001

15,001

15,001

0

0

0

0

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from long-term debt

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of debt

4,500

6,000

5,000

6,250

6,250

3,750

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repurchases of common stock

18,960

17,961

65,477

77,586

66,102

73,105

27,630

29,000

37,142

43,792

59,296

62,314

50,656

37,003

0

0

0

-

-

-

-

0

-

-

-

-

Net cash provided by (used in) financing activities

85,486

-24,225

-70,582

-82,031

-66,884

-88,117

-43,734

4,788

-3,787

8,104

-4,246

-55,333

-45,668

-33,670

-14,855

386

553

55,813

55,461

55,526

54,941

46,686

46,154

0

0

0

Net increase in cash and cash equivalents

99,877

30,984

25,985

7,881

6,469

-35,866

-6,319

44,862

67,960

61,837

38,234

-20,178

-50,577

-26,263

-12,668

61,877

-21,637

44,214

49,257

-36,105

45,044

24,895

12,266

0

0

0

Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest

2,429

2,478

2,331

2,776

2,341

2,084

2,191

1,180

1,019

651

0

0

0

-

-

-

-

-

-

7

9

9

8

0

0

0

Right-of-use asset obtained in exchange for lease obligation - lease amendment

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures of cash flow information:
Cash paid during the period for:
Financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

Income taxes, net

13,187

6,673

6,981

3,324

-4,305

2,281

3,584

6,788

10,638

10,542

0

0

0

-

-

-

-

482

482

0

0

0

-

-

-

-

Non-cash operating activities
Landlord contribution to leasehold improvements recorded as deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Contingent consideration - business acquisitions

-

-

-

-

-

-

-

-

-

-

-

-

-

22,470

6,370

6,370

6,370

0

0

0

0

0

-

-

-

-

Conversion of note payable to Preferred Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Franchise taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

9

0

0

0

Accrued follow-on public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

0

-